FibroGen, Inc (NASDAQ:FGEN) – Jefferies Group dropped their Q3 2017 earnings per share estimates for FibroGen in a note issued to investors on Monday. Jefferies Group analyst M. Yee now anticipates that the biopharmaceutical company will post earnings per share of ($0.49) for the quarter, down from their prior estimate of ($0.42). Jefferies Group has a “Buy” rating and a $75.00 price objective on the stock. Jefferies Group also issued estimates for FibroGen’s Q4 2017 earnings at ($0.49) EPS, FY2017 earnings at ($1.98) EPS and FY2018 earnings at ($0.91) EPS.
FibroGen (NASDAQ:FGEN) last announced its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by $0.01. The company had revenue of $29 million for the quarter, compared to analysts’ expectations of $34.80 million. FibroGen had a negative net margin of 105.59% and a negative return on equity of 64.42%. COPYRIGHT VIOLATION WARNING: This story was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://stocknewstimes.com/2017/08/12/fibrogen-inc-expected-to-post-q3-2017-earnings-of-0-49-per-share-fgen.html.
FGEN has been the subject of several other reports. Citigroup Inc. lifted their price objective on shares of FibroGen from $48.00 to $65.00 and gave the stock a “top pick” rating in a research note on Tuesday. BidaskClub downgraded shares of FibroGen from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. William Blair reiterated an “outperform” rating on shares of FibroGen in a research note on Wednesday. Stifel Nicolaus reiterated a “buy” rating and set a $38.00 price objective (up from $32.00) on shares of FibroGen in a research note on Thursday, June 22nd. Finally, Goldman Sachs Group, Inc. (The) downgraded shares of FibroGen from a “buy” rating to a “neutral” rating and set a $31.00 price objective for the company. in a research note on Friday, July 21st. One research analyst has rated the stock with a sell rating, one has issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $60.17.
Shares of FibroGen (NASDAQ FGEN) opened at 41.65 on Thursday. The stock’s market capitalization is $2.97 billion. The firm’s 50-day moving average is $34.92 and its 200-day moving average is $28.29. FibroGen has a 52 week low of $15.60 and a 52 week high of $51.70.
In related news, CEO Thomas B. Neff sold 38,636 shares of the firm’s stock in a transaction on Wednesday, May 31st. The shares were sold at an average price of $26.21, for a total transaction of $1,012,649.56. Following the completion of the transaction, the chief executive officer now owns 3,345,941 shares of the company’s stock, valued at $87,697,113.61. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider K Peony Yu sold 3,721 shares of the firm’s stock in a transaction on Wednesday, June 14th. The stock was sold at an average price of $28.95, for a total transaction of $107,722.95. Following the transaction, the insider now directly owns 221,507 shares of the company’s stock, valued at approximately $6,412,627.65. The disclosure for this sale can be found here. In the last three months, insiders have sold 537,474 shares of company stock valued at $19,220,138. 14.90% of the stock is currently owned by corporate insiders.
Several hedge funds and other institutional investors have recently modified their holdings of FGEN. Ameritas Investment Partners Inc. acquired a new position in shares of FibroGen during the first quarter valued at about $111,000. Quantbot Technologies LP acquired a new position in shares of FibroGen during the second quarter valued at about $128,000. SG Americas Securities LLC boosted its position in shares of FibroGen by 6.5% in the second quarter. SG Americas Securities LLC now owns 6,747 shares of the biopharmaceutical company’s stock valued at $218,000 after buying an additional 412 shares during the period. Airain ltd acquired a new position in shares of FibroGen during the first quarter valued at about $236,000. Finally, Amalgamated Bank acquired a new position in shares of FibroGen during the second quarter valued at about $237,000. 43.45% of the stock is owned by hedge funds and other institutional investors.
FibroGen, Inc is a science-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.
Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.